Core Lab Announces $60,000,000 At-the-Market Equity Offering Program

Rhea-AI Summary

Core Laboratories N.V. (NYSE: CLB) has launched an at-the-market equity offering program, allowing it to sell common shares worth up to $60 million. The equity distribution agreement with Wells Fargo Securities enables sales through various methods, adhering to legal and NYSE regulations. Proceeds will be used for general corporate purposes, including product development and potential acquisitions. The offering relies on an existing shelf registration statement with the SEC. Core Lab does not guarantee any sales under this agreement and may suspend it at any time.

Positive

• Launch of an at-the-market equity offering program up to $60 million.
• Proceeds are earmarked for general corporate purposes, potentially strengthening the company's financial position.

Negative

• Possible dilution of existing shareholders due to stock sales.
• Equity distribution agreement may be suspended or terminated based on market conditions.

AMSTERDAM, Dec. 17, 2020 /PRNewswire/ -- Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") ("Core," "Core Lab," or the "Company") announced today that it has established an at-the-market equity offering program (the "ATM Program") under which it may, from time to time, sell its common shares having an aggregate sales price of up to $60,000,000 (the "Shares"), and has entered into an equity distribution agreement ("Equity Distribution Agreement") with Wells Fargo Securities, LLC ("Wells Fargo Securities"), as sales agent.

Upon delivery of a placement notice and subject to the terms and conditions of the Equity Distribution Agreement, Wells Fargo Securities will use reasonable efforts consistent with its normal trading and sales practices, applicable laws and the rules of the New York Stock Exchange to sell the Shares from time to time based upon Core Lab's instructions for the sales, including price, time or size limits specified by Core Lab. Pursuant to the Equity Distribution Agreement, sales of the Shares may be made by any method permitted by law, including in ordinary brokers' transactions, negotiated transactions, block trades, and transactions deemed to be "at-the-market offerings," as defined in Rule 415 under the Securities Act of 1933, as amended. Wells Fargo Securities' obligations to sell the Shares under the Equity Distribution Agreement are subject to satisfaction of certain conditions, including customary closing conditions.

Core Lab has agreed to reimburse Wells Fargo Securities for certain specified expenses and has also agreed to provide Wells Fargo Securities with customary indemnification and contribution rights. Core Lab is not obligated to sell any Shares under the Equity Distribution Agreement and may at any time suspend solicitation and offers under the Equity Distribution Agreement. The Equity Distribution Agreement may be terminated by Core Lab at any time by giving written notice to Wells Fargo Securities for any reason or by Wells Fargo Securities at any time by giving written notice to Core Lab for any reason, or immediately under certain circumstances, including, but not limited to, the occurrence of a material adverse change in the Company. The ATM Program pursuant to the Equity Distribution Agreement will automatically terminate upon the issuance and sale of all of the Shares through Wells Fargo Securities.

Core Lab intends to use the net proceeds from the sales of the Shares, if any, for general corporate purposes, which may include, among other things, investments in the development of new products and technology, capital expenditures, repayments of indebtedness, working capital and potential acquisitions. Pending these uses, Core Lab intends to invest the net proceeds in investment-grade interest-bearing obligations, highly liquid cash equivalents, certificates of deposit, or direct or guaranteed obligations of the United States of America.

The Shares will be offered under the Company's existing shelf registration statement on Form S-3ASR (File No.: 333-245691) filed with the Securities and Exchange Commission (the "SEC"). The offering is being made by means of a prospectus supplement to the prospectus contained in the registration statement. Before making an investment in the Shares, potential investors should read the prospectus and the prospectus supplement for more complete information about Core Lab and the offering. Potential investors may obtain these documents for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, the Company or Wells Fargo Securities will arrange, upon request, to send the prospectus. Please direct requests to: Wells Fargo Securities by mail at 500 West 33rd Street, New York, NY 10001, Attention: Equity Syndicate Department, by email to cmclientsupport@wellsfargo.com or by telephone at (800) 326-5897.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world.

This release, as well as other statements we make, includes forward-looking statements regarding the future revenue, profitability, business strategies and developments of the Company made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates, public health crises, such as the COVID-19 pandemic, and any related actions taken by businesses and governments, and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC. These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.

Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/core-lab-announces-60-000-000-at-the-market-equity-offering-program-301195081.html

SOURCE Core Laboratories N.V.

FAQ

What is Core Laboratories' equity offering program?

Core Laboratories has initiated an at-the-market equity offering program to sell shares worth up to $60 million.

What are the intended uses for proceeds from the CLB offering?

Proceeds from the offering will be used for general corporate purposes, including product development and potential acquisitions.

Who is managing Core Lab's equity distribution agreement?

Wells Fargo Securities is the sales agent managing Core Lab's equity distribution agreement.

How might the equity offering affect CLB shareholders?

The equity offering could lead to dilution of existing shareholders due to the potential increase in common shares.

Can Core Lab suspend the equity offering program?

Yes, Core Lab can suspend or terminate the equity distribution agreement at any time.